TPG Capital and Vida Ventures Invest $225M in Asklepios BioPharmaceutical (AskBio)

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

TPG Completes Majority Investment in iNova Pharmaceuticals

October 31, 2022

Pharmaceuticals

TPG (through its Asia platform) completed a majority investment in iNova Pharmaceuticals, a multinational consumer health and pharmaceutical company, with existing investor Pacific Equity Partners re-investing as a minority co-investor. The deal will support iNova's regional expansion and growth strategy across Southeast and North Asia, and fund channel expansion, product-in-fill and technology investments.

Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories

January 8, 2019

Healthcare Services

Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.

TPG Growth Makes Minority Investment in AnovoRx

January 12, 2022

Healthcare Services

TPG Growth has made a significant minority investment in AnovoRx Holdings, Inc. (Anovo), a specialty pharmacy and patient-support services provider that partners with biopharmaceutical manufacturers to deliver therapies to patients with rare and complex diseases. Financial terms were not disclosed; TPG said the investment will help Anovo expand its service offering, scale operations, and deepen relationships with manufacturer clients and patients.

TPG Growth Invests $30M in Solara Active Pharma

February 4, 2019

Pharmaceuticals

TPG Growth will invest $30 million in Solara Active Pharma to support the Indian API manufacturer's growth and capacity expansion into regulated markets. The minority growth equity investment is intended to help Solara scale manufacturing and R&D capabilities and strengthen its position with global generic customers in the US and Europe.